生命科学资讯

Chutes & Ladders—Roche taps Aussie oncologist to lead early research

Roche taps Aussie oncologist to lead research—Chutes & Ladders - Fierce Biotech

A circadian rheostat drives proton electrochemical gradients to optimize cell-type-specific growth in Arabidopsis

Roche to end manufacturing of key antibiotic amid EU’s generic woes - Euractiv

Paragon's new biotech Korsana tackles Alzheimer's like Roche

Paragon's latest biotech will try to slow Alzheimer's like Roche - Endpoints News

Ngs Oncology Market Is Going to Boom | Illumina • Roche • Thermo Fisher Scientific - openPR.com

Number of Roche Group employees from 2007 to 2025 - Statista

Lilly bets again on China drugs; Roche showcases MS data

#ACTRIMS26: Roche’s MS drug fenebrutinib beats Ocrevus, cutting risk of disability progression by 12%

Roche’s fenebrutinib demonstrates decade-first benefit in multiple sclerosis - European Pharmaceutical Review

Roche unveils data behind BTK inhibitor's phase 3 multiple sclerosis win in Ocrevus trial - Fierce Biotech

Roche’s Genentech cut at least 489 jobs last year, new disclosure reveals

Genentech cut at least 489 jobs last year, new filing reveals - Fierce Biotech

Roche's return to RNA continues with $1.7B deal for Sanegene program

Roche continues RNA return with $1.7B deal for Sanegene drug - Fierce Biotech

Roche Expands Clinical Research in Mexico, Invests MX$1.2 Billion - Mexico Business News

Roche’s 2025 profit blunted by weakened US dollar - Medical Device Network

Roche’s 2025 profit blunted by weakened US dollar - Pharmaceutical Technology